Search

Displaying results 851 - 860 of 2420 in total
  1. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  2. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further develo...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  3. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: Cytochrome P-450 CYP3A Inhibitors, P-glycoprotein substrates
  5. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: Cytochrome P-450 CYP1A2 Substrates, P-glycoprotein substrates
  6. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the spo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumo...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

    Synonyms: (±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  10. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Inhibitors